LEADER 04077nam 22006974a 450 001 9910143740603321 005 20170815120952.0 010 $a1-280-27526-X 010 $a9786610275267 010 $a0-470-02142-X 010 $a0-470-02141-1 035 $a(CKB)1000000000357241 035 $a(EBL)232685 035 $a(OCoLC)475938763 035 $a(SSID)ssj0000170472 035 $a(PQKBManifestationID)11171219 035 $a(PQKBTitleCode)TC0000170472 035 $a(PQKBWorkID)10223946 035 $a(PQKB)10515328 035 $a(MiAaPQ)EBC232685 035 $a(EXLCZ)991000000000357241 100 $a20041130d2005 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 04$aThe hERG cardial potassium channel$b[electronic resource] $estructure, function, and long QT syndrome /$f[editors, Derek J. Chadwick, James Goode] 210 $aNew York $cJ. Wiley$d2005 215 $a1 online resource (309 p.) 225 1 $aNovartis Foundation symposium ;$v266 300 $aBased on a symposium. 311 $a0-470-02140-3 320 $aIncludes bibliographical references and indexes. 327 $aTHE hERG CARDIAC POTASSIUM CHANNEL: STRUCTURE, FUNCTION AND LONG QT SYNDROME; Contents; Participants; Chair's introduction; Gating and assembly of heteromeric hERG1a/1b channels underlying I(Kr) in the heart; Discussion; Structure-function studies of the outer mouth and voltage sensor domain of hERG; Discussion; General discussion I; Voltage sensor movement in the hERGK(+) channel; Discussion; hERG channel trafficking; Discussion; Dynamic control of hERG/I(Kr) by PKA-mediated interactions with 14-3-3; Discussion; General discussion II 327 $aDoes hERG coassemble with a b subunit? Evidence for roles of MinK and MiRP1Discussion; hERG block, QT liability and sudden cardiac death; Discussion; Structural determinants for high-affinity block of hERG potassium channels; Discussion; Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs; Discussion; In silico modelling-pharmacophores and hERG channel models; Discussion; The long QTsyndrome: a clinical counterpart of HERG mutations; Discussion; Cellular mechanisms of Torsade de Pointes; Discussion 327 $aExpression and role of hERG channels in cancer cellsDiscussion; TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability); Discussion; Drug-induced QT interval prolongation: regulatory guidance and perspectives on hERG channel studies; Discussion; Closing remarks; Index of contributors; Subject index 330 $aThis book draws together contributions from basic, pharmaceutical and clinical sciences aimed at a better understanding of the structure and function of hERG and the molecular basis for compound binding. It features regulatory authority perspectives on preferred preclinical test systems and includes topics on hERG channel gating, regulation of functional expression, pharmacological properties of hERG/IKr channels, drug-induced long QT syndrome and preclinical evaluation and regulatory recommendations for assessing QT prolongation risks. Better understanding of the role of the hERG channe 410 0$aNovartis Foundation symposium ;$v266. 606 $aPotassium channels$vCongresses 606 $aLong QT syndrome$vCongresses 606 $aHeart$xPhysiology$vCongresses 606 $aHeart$xPathophysiology$vCongresses 608 $aElectronic books. 615 0$aPotassium channels 615 0$aLong QT syndrome 615 0$aHeart$xPhysiology 615 0$aHeart$xPathophysiology 676 $a612.1/7 676 $a612.173 676 $a616.1207 701 $aChadwick$b Derek$091632 701 $aGoode$b Jamie$0283336 712 02$aNovartis Foundation. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910143740603321 996 $aThe hERG cardial potassium channel$92149295 997 $aUNINA LEADER 04310nam 22005895 450 001 9910151663203321 005 20250610110622.0 010 $a3-319-44344-5 024 7 $a10.1007/978-3-319-44344-7 035 $a(CKB)3710000000952846 035 $a(DE-He213)978-3-319-44344-7 035 $a(MiAaPQ)EBC4744027 035 $a(PPN)197140793 035 $a(MiAaPQ)EBC29095355 035 $a(EXLCZ)993710000000952846 100 $a20161115d2017 u| 0 101 0 $aeng 135 $aurnn#008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aQuick Guide to Good Clinical Practice $eHow to Meet International Quality Standard in Clinical Research /$fby Cemal Cingi, Nuray Bayar Muluk 205 $a1st ed. 2017. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2017. 215 $a1 online resource (XVIII, 237 p.) 311 08$a3-319-44343-7 320 $aIncludes bibliographical references. 327 $a1 Clinical Trials: Historical Aspects and Importance and New Drug Developments -- 2 The Definition of GCP -- 3 The Principles of GCP -- 4 The Drug Development Process and Evolution of Regulations -- 5 Planning Clinical Research -- 6 Preparation of Ethics Committee (IRB) Proposal -- 7 Preparation of Informed Consent -- 8 Preparation of Findings Tables -- 9 Setting the Ideal Statistical Methods -- 10 The Duties of a Clinical Research Coordinator -- 11 The Duties of Clinical Researchers -- 12 The Phases of Clinical Studies -- 13 Safety in Clinical Trials -- 14 Setting the Size -- 15 Setting the Ideal Method -- 16 Ethics of Clinical Research -- 17 Recruitment and Enrolment -- 18 Why we need Clinical Consent and Other Documentation -- 19 Monitoring the Trial -- 20 Inspection -- 21 Ethics - Institutional Review Board/Independent Ethics Committee(IRB/IEC) -- 22 Responsibilities of the Investigator -- 23 Responsibilities of the Sponsor -- 24.Clinical Trial Protocols. 330 $aThis brand-new book offers a reference guide to understanding and applying the rules for properly conducting clinical trials to meet the international quality standard ? Good Clinical Practice ? provided by the International Conference on Harmonization (ICH). The work offers an updated perspective on the clinical research landscape within the context of the clinical trial regulatory frameworks in Europe and the USA. In addition to providing a historical review and a detailed definition of GPC regulations, it includes step-by-step explanations of all the requirements that researchers should bear in mind when designing and performing new trials. Further topics covered include: ethics of clinical research; the drug development process and evolution of regulations; investigator and sponsor responsibilities; and clinical trial protocols. Written by clinicians for clinicians, the book represents a valuable read also for researchers, pharmacists and all professionals involved in applications to the ethic committees, whose approval is required for new clinical studies. 606 $aPharmacy 606 $aStatistics 606 $aSurgery 606 $aMedical education 606 $aDrug Safety and Pharmacovigilance$3https://scigraph.springernature.com/ontologies/product-market-codes/H69010 606 $aStatistics for Life Sciences, Medicine, Health Sciences$3https://scigraph.springernature.com/ontologies/product-market-codes/S17030 606 $aGeneral Surgery$3https://scigraph.springernature.com/ontologies/product-market-codes/H59044 606 $aMedical Education$3https://scigraph.springernature.com/ontologies/product-market-codes/O26000 615 0$aPharmacy. 615 0$aStatistics. 615 0$aSurgery. 615 0$aMedical education. 615 14$aDrug Safety and Pharmacovigilance. 615 24$aStatistics for Life Sciences, Medicine, Health Sciences. 615 24$aGeneral Surgery. 615 24$aMedical Education. 676 $a353.998 700 $aCingi$b Cemal$4aut$4http://id.loc.gov/vocabulary/relators/aut$0788865 702 $aBayar Muluk$b Nuray$4aut$4http://id.loc.gov/vocabulary/relators/aut 906 $aBOOK 912 $a9910151663203321 996 $aQuick Guide to Good Clinical Practice$92516855 997 $aUNINA